Bronşektazide Pulmoner Rehabilitasyon

Yıl 2023, Cilt: 5 Sayı: 1, 70 - 80, 28.02.2023

Şeyda Yıldız , Esra Pehlivan

https://doi.org/10.57224/jhpr.1065841

Öz

Bronşektazi; bronşların anormal, kalıcı ve geri dönüşü olmayan dilatasyonu ile karakterize klinik olarak öksürük, balgam üretimi ve tekrarlayan solunum yolu enfeksiyonlarına neden olan kronik inflamatuar bir akciğer hastalığıdır. Bronşektazinin altta yatan birçok nedeni vardır. Bronşektazide pulmoner rehabilitasyon; egzersiz eğitimi, hava yolu temizleme teknikleri, kas-iskelet sistemine yönelik yaklaşımlar, solunum işini azaltmaya dayalı teknikler ve hasta eğitimini içermektedir. Bronşektazili hastalara kişiselleştirilmiş pulmoner rehabilitasyon programları planlanıp uygulanması yaşam kalitesini ve fiziksel kapasiteyi artırmak açısından oldukça değerlidir. Rehabilitasyonun uzun vadeli sonuçları ile ilgili daha fazla çalışmaya ihtiyaç vardır. Geleneksel pulmoner rehabilitasyon programlarının bronşektazi için optimize edilmesi gerekmektedir.

Anahtar Kelimeler

Bronşektazi, havayolu temizliği, pulmoner rehabilitasyon

Pulmonary Rehabilitation in Bronchiectasis

Öz

Bronchiectasis; It is a chronic inflammatory lung disease characterized by abnormal, persistent and irreversible dilation of the bronchi, clinically causing cough, sputum production and recurrent respiratory tract infections. There are many underlying causes of bronchiectasis. Pulmonary rehabilitation in bronchiectasis; exercise training, airway clearance techniques, musculoskeletal approaches, techniques based on reducing work of breathing, and patient education. Planning and implementing personalized pulmonary rehabilitation programs for patients with bronchiectasis is very valuable in terms of increasing the quality of life and physical capacity. More studies are needed on the long-term outcomes of rehabilitation. Traditional pulmonary rehabilitation programs need to be optimized for bronchiectasis.

Anahtar Kelimeler

Bronchiectasis, airway clearance, pulmonary rehabilitation

Kaynakça

• 1. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol [Internet]. 2013;55(1):27–34. Available from: https://www.sciencedirect.com/science/article/pii/S0161589012004129
• 2. Chandrasekaran R, Mac Aogáin M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018 May;18(1):83.
• 3. Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. Lancet [Internet]. 2018;392(10150):866–79. Available from: https://www.sciencedirect.com/science/article/pii/S014067361831554X
• 4. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100(12):2183–9.
• 5. de Camargo AA, Boldorini JC, Holland AE, de Castro RAS, Lanza F de C, Athanazio RA, et al. Determinants of Peripheral Muscle Strength and Activity in Daily Life in People With Bronchiectasis. Phys Ther. 2018 Mar;98(3):153–61.
• 6. Gao Y-H, Guan W-J, Liu S-X, Wang L, Cui J-J, Chen R-C, et al. Aetiology of bronchiectasis in adults: A systematic literature review. Respirology. 2016 Nov;21(8):1376–83.
• 7. Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon T, et al. Standardised classification of the aetiology of bronchiectasis using an objective algorithm. Vol. 50, The European respiratory journal. England; 2017.
• 8. Bush A, Floto RA. Pathophysiology, causes and genetics of paediatric and adult bronchiectasis. Respirology. 2019 Nov;24(11):1053–62.
• 9. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65 Suppl 1:i1-58.
• 10. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015 May;45(5):1446–62.
• 11. Olcay S. Pulmonary Rehabilitation In Bronchiectasis Bronşektazide Pulmoner Rehabilitasyon. In: Güncel Göğüs Hastalıkları Serisi. 2019. p. 101–6.
• 12. Quint JK, Millett ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016 Jan;47(1):186–93.
• 13. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J [Internet]. 2017 Sep 1;50(3):1700629. Available from: http://erj.ersjournals.com/content/50/3/1700629.abstract
• 14. McShane PJ, Naureckas ET, Tino G, Strek ME. Non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.
• 15. Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018 Sep;6(9):715–26.
• 16. Snijders D, Fernandez Dominguez B, Calgaro S, Bertozzi I, Escribano Montaner A, Perilongo G, et al. Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence? Vol. 28, International journal of immunopathology and pharmacology. England; 2015. p. 150–9.
• 17. Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, et al. Spanish Guidelines on Treatment of Bronchiectasis in Adults. Arch Bronconeumol. 2018 Feb;54(2):88–98.
• 18. Swaminathan S, Kuppurao K V, Somu N, Vijayan VK. Reduced exercise capacity in non-cystic fibrosis bronchiectasis. Indian J Pediatr. 2003 Jul;70(7):553–6.
• 19. Liaw M-Y, Wang Y-H, Tsai Y-C, Huang K-T, Chang P-W, Chen Y-C, et al. Inspiratory muscle training in bronchiectasis patients: a prospective randomized controlled study. Clin Rehabil. 2011 Jun;25(6):524–36.
• 20. Ozalp O, Inal-Ince D, Calik E, Vardar-Yagli N, Saglam M, Savci S, et al. Extrapulmonary features of bronchiectasis: muscle function, exercise capacity, fatigue, and health status. Multidiscip Respir Med. 2012 Jun;7(1):3.
• 21. McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016;71(12):1110–8.
• 22. de Camargo AA, de Castro RAS, Vieira RP, Oliveira-Júnior MC, Araujo AA de, De Angelis K, et al. Systemic Inflammation and Oxidative Stress in Adults with Bronchiectasis: Association with Clinical and Functional Features. Clinics (Sao Paulo). 2021;76:e2474.
• 23. Spinou A, Fragkos KC, Lee KK, Elston C, Siegert RJ, Loebinger MR, et al. The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. Thorax. 2016 Aug;71(8):683–94.
• 24. Dilek K, YILDIZ H. Dispne semptomunun değerlendirilmesinde dispne ölçeklerinin etkinlikleri ve kullanım sıklıkları. Gümüşhane Üniversitesi Sağlık Bilim Derg. 2013;2(1):137–49.
• 25. Yildiz S, Inal-Ince D, Calik-Kutukcu E, Vardar-Yagli N, Saglam M, Arikan H, et al. Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis. Lung [Internet]. 2018;196(3):343–9. Available from: https://doi.org/10.1007/s00408-018-0094-x
• 26. Korkmaz S, CANITEZ Y, Çekiç Ş, Efe HP, Ocakoğlu G, Sapan N. Kistik fibrozis dışı bronşektazi tanılı olguların değerlendirilmesi. Güncel Pediatr. 2018;16(2):106–16.
• 27. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct;188(8):e13-64.
• 28. Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Vol. 202, The Medical journal of Australia. Australia; 2015. p. 130.
• 29. Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019 Jan;74(Suppl 1):1–69.
• 30. Al-Jahdali H, Alshimemeri A, Mobeireek A, Albanna AS, Al Shirawi NN, Wali S, et al. The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. Ann Thorac Med. 2017;12(3):135–61.
• 31. Muñoz G, de Gracia J, Buxó M, Alvarez A, Vendrell M. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. Eur Respir J. 2018 Jan;51(1).
• 32. Vendrell M, de Gracia J, Olveira C, Martinez-Garcia MA, Girón R, Máiz L, et al. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch Bronconeumol. 2008 Nov;44(11):629–40.
• 33. DURMUŞ BB, Atalay T, YURDALAN U. Erişkin ve Geriatrik Bireylerde Kardiyopulmoner Rehabilitasyon Gerektiren Hastalıklar. Cumhur Üniversitesi Sağlık Bilim Enstitüsü Derg. 2021;6(2):69–81.
• 34. Lee AL, Hill CJ, McDonald CF, Holland AE. Pulmonary Rehabilitation in Individuals With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review. Arch Phys Med Rehabil. 2017 Apr;98(4):774-782.e1.
• 35. Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane database Syst Rev. 2015 Nov;2015(11):CD008351.
• 36. O’Neill K, O’Donnell AE, Bradley JM. Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis. Respirology. 2019 Mar;24(3):227–37.
• 37. Mandal P, Sidhu MK, Kope L, Pollock W, Stevenson LM, Pentland JL, et al. A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis. Respir Med. 2012 Dec;106(12):1647–54.
• 38. Franks LJ, Walsh JR, Hall K, Jacuinde G, Yerkovich S, Morris NR. Comparing the Performance Characteristics of Different Positive Expiratory Pressure Devices. Respir Care [Internet]. 2019;64(4):434–44. Available from: http://rc.rcjournal.com/content/64/4/434
• 39. Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane database Syst Rev. 2017 Sep;9(9):CD011699.
• 40. Tambascio J, de Souza HCD, Martinez R, Baddini-Martinez JA, Barnes PJ, Gastaldi AC. Effects of an Airway Clearance Device on Inflammation, Bacteriology, and Mucus Transport in Bronchiectasis. Respir Care. 2017 Aug;62(8):1067–74.
• 41. Tambascio J, de Souza LT, Lisboa RM, Rita de Cássia VP, de Souza HCD, Gastaldi AC. The influence of Flutter® VRP1 components on mucus transport of patients with bronchiectasis. Respir Med. 2011;105(9):1316–21.
• 42. Sharma P, Prem V, Jain S. Immediate Effects of Acapella(®) on Dynamic Lung Compliance in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome: A Case Series. Indian J Crit care Med peer-reviewed, Off Publ Indian Soc Crit Care Med. 2018 Feb;22(2):100–2.
• 43. Volsko TA, DiFiore JM, Chatburn RL. Performance Comparison of Two Oscillating Positive Expiratory Pressure Devices: Acapella Versus Flutter. Respir Care [Internet]. 2003;48(2):124–30. Available from: http://rc.rcjournal.com/content/48/2/124
• 44. McCormack P, Burnham P, Southern KW. Autogenic drainage for airway clearance in cystic fibrosis. Cochrane database Syst Rev. 2017 Oct;10(10):CD009595.
• 45. Poncin W, Reychler G, Leeuwerck N, Bauwens N, Aubriot A-S, Nader C, et al. Short-Term Effect of Autogenic Drainage on Ventilation Inhomogeneity in Adult Subjects With Stable Non-Cystic Fibrosis Bronchiectasis. Respir Care. 2017 May;62(5):524–31.
• 46. Wong C, Sullivan C, Jayaram L. ELTGOL airway clearance in bronchiectasis: laying the bricks of evidence. Eur Respir J [Internet]. 2018;51(1). Available from: https://erj.ersjournals.com/content/51/1/1702232
• 47. Herrero-Cortina B, Vilaró J, Martí D, Torres A, San Miguel-Pagola M, Alcaraz V, et al. Short-term effects of three slow expiratory airway clearance techniques in patients with bronchiectasis: a randomised crossover trial. Physiotherapy. 2016;102(4):357–64.
• 48. Chalmers JD, Sethi S. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim care Respir Med. 2017 Mar;27(1):18.
• 49. Saygı EK, Coşkun ÖK. Kistik fibrozis hastalarında pulmoner rehabilitasyon. Turkish J Phys Med Rehabil Fiz Tip ve Rehabil Derg. 2017;63(1).
• 50. Ramos EMC, Ramos D, Moreira GL, Macchione M, Guimarães ET, Rodrigues FMM, et al. Viscoelastic Properties of Bronchial Mucus After Respiratory Physiotherapy in Subjects With Bronchiectasis. Respir Care [Internet]. 2015;60(5):724–30. Available from: http://rc.rcjournal.com/content/60/5/724
• 51. Bilton D, Daviskas E, Anderson SD, Kolbe J, King G, Stirling RG, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013 Jul;144(1):215–25.
• 52. Lee AL, Hill CJ, Cecins N, Jenkins S, McDonald CF, Burge AT, et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis--a randomised controlled trial. Respir Res. 2014 Apr;15(1):44.
• 53. Sawyer A, Cavalheri V, Hill K. Effects of high intensity interval training on exercise capacity in people with chronic pulmonary conditions: a narrative review. BMC Sport Sci Med Rehabil. 2020;12:22.
• 54. Kabitz H-J, Lang F, Walterspacher S, Sorichter S, Müller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006 Nov;130(5):1496–502.
• 55. Lötters F, van Tol B, Kwakkel G, Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J. 2002 Sep;20(3):570–6.
• 56. Koulouris NG, Retsou S, Kosmas E, Dimakou K, Malagari K, Mantzikopoulos G, et al. Tidal expiratory flow limitation, dyspnoea and exercise capacity in patients with bilateral bronchiectasis. Eur Respir J. 2003 May;21(5):743–8.
• 57. Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, et al. An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2015 Dec;192(11):1373–86.
• 58. Pehlivan E, Niksarlıoğlu EY, Balcı A, Kılıç L. The Effect of Pulmonary Rehabilitation on the Physical Activity Level and General Clinical Status of Patients with Bronchiectasis. Turkish Thorac J. 2019 Jan;20(1):30–5.
• 59. José A, Holland AE, Selman JPR, de Camargo CO, Fonseca DS, Athanazio RA, et al. Home-based pulmonary rehabilitation in people with bronchiectasis: a randomised controlled trial. ERJ open Res. 2021 Apr;7(2).
• 60. Burdea GC. Virtual rehabilitation--benefits and challenges. Methods Inf Med. 2003;42(5):519–23.
• 61. Rutkowski S, Rutkowska A, Kiper P, Jastrzebski D, Racheniuk H, Turolla A, et al. Virtual Reality Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis. 2020;15:117–24.